1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Drug Pricing Reform In US: It’s Over For 2017

 
• By Ramsey Baghdadi

There's lots of buzz about drug pricing actions, be they executive or legislative. But the die is cast for this year: real reforms will have to wait.

White House

Just before the US Presidential election last year, a group of health policy experts representing Democrats and Republicans who might potentially be tapped for high-level healthcare positions in a new administration held a roundtable with reporters. The one area of consensus was that 2017 would be the year Congress finally addresses drug pricing in a meaningful way.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

 
• By Leslie Small

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Europe Should Pay Drug Prices More In Line With US, Two Pharma CEOs Argue

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.